5

10

15

20

25

WHAT IS CLAIMED AS NEW AND IS DESIRED TO BE SECURED BY LETTERS PATENT OF THE UNITED STATES IS:

- 1. A method of treating a cancer in a patient in need thereof comprising administering in vivo a therapeutically effective amount of a composition comprising:
- (i) an expression vector containing a gene encoding p21;
 - (ii) a pharmaceutical carrier.
- The method of Claim 1, wherein said expression vector is a eukaryotic or viral vector.
- 3. The method of Claim 2, wherein said viral vector is an adenoviral vector.
- 4. The method of Claim 1, wherein said cancer is melanoma.
- 5. The method of Claim 1, wherein said cancer is renal cell carcinoma.
- 6. The method of Claim 1, wherein said expression vector is encapsulated in a liposome.
- 7. The method of claim 1, wherein said patient is human.
- 8. The method of Claim 1, wherein said composition comprises 10¹⁰ expression vectors per ml.
- 9. The method of claim 1, wherein said composition further comprises an immunotherapeutic agent, genetic therapeutic, cytokine, prodrug converting enzyme or anticancer agent.
- 10. The method of claim 1, wherein said composition further comprises a second expression vector comprising a gene

5

10

15

20

25

encoding an immunotherapeutic agent, genetic therapeutic, cytokine or prodrug converting enzyme.

11. The method of claim 1, wherein said expression vector further comprises a second gene encoding an immunotherapeutic agent, genetic therapeutic, cytokine or prodrug converting enzyme;

wherein said second gene is in the same reading frame as said gene encoding p21.

- 12. A method of treating restenosis in a patient in need thereof comprising administering in vivo a therapeutically effective amount of a composition comprising:
- (i) an expression vector containing the gene which encodes p21; and
 - (ii) a pharmaceutical carrier.
- 13. A method of treating a cancer in a patient in need thereof comprising administering in vivo a therapeutically effective amount of a composition comprising:
- (i) an expression vector comprising a gene encoding p21 fused to a gene encoding a prodrug converting enzyme.
- 14. The method of claim 13, wherein said prodrug converting enzyme is thymidine kinase, cytosine deaminase or β -glucurodinase.
- 15. The method of claim 14, wherein said composition further comprises a pharmaceutically acceptable carrier.
- 16. The method of claim 14, wherein said expression vector is a viral vector.

